Mayne Pharma GroupMYX 
-0.25%24h
Mayne Pharma Group (MYX) Stock Overview
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
MYX Stock Information
Mayne Pharma Group (MYX) Price Chart
Mayne Pharma Group Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $2.64 | N/A |
| Market Cap | $217.16M | N/A |
| Shares Outstanding | 82.18M | -0.15% |
| Employees | 0 | N/A |
| Shareholder Equity | 634.36M | 13.86% |
Valuation | 2023 | Change |
|---|---|---|
| P/S Ratio | 1.78 | N/A |
| P/B Ratio | 0.34 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | 0.1239 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $122.33M | N/A |
| Earnings | $78.58M | N/A |
| Gross Margin | 0.4512 | N/A |
| Operating Margin | -1.05 | N/A |
| Net income margin | 0.6423 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $836.62M | N/A |
| Total Debt | $31.86M | N/A |
| Cash on Hand | $147.65M | N/A |
| Debt to Equity | 0.6481 | -26.33% |
| Cash to Debt | $4.63 | 1882.95% |
| Current Ratio | $1.78 | 112.42% |
